



FINISHED FORMULATIONS BASED ON PROBIOTIC SF68®

Diarrhea & Dysbiosis
by antibiotics (drug)

Dyslipidemias
& Obesity

Acne & Seborrheic
dermatitis

IBS

Contact: **Federico Bianchi** - Sales & Marketing Manager
federico.bianchi@cerbios.ch

The HAS Group


Headquarters and **production sites** in **Switzerland**, plus a U.S. based entity, to ensure a **global presence** of the Group

Manufacturing sites in Switzerland

1. Biasca, Ticino – **HAS Healthcare Advanced Synthesis SA**
2. Barbengo (Lugano), Ticino – **Cerbios-Pharma SA**
3. Couvet, Neuchâtel – **GMT Fine Chemicals SA**

U.S. Entity

- Delaware, USA – **HAS Synthesis LLC**



Fact sheet – The Group



HAS Healthcare
Advanced Synthesis



3

Manufacturing
Sites in
Switzerland

50y

of experience

425

Employees

2

R&D Centers

ADCs

Center of
Excellence

Expertise

in chemical and biotech
for top-tier CDMO services,
specializing in HPAPIs,
oncology, and ADCs

Experience


from early phase to process
scale up


> 60

countries
presence

Microbiota and its role over the gut

- Microbiota (intestinal flora, MBI) has a role over the classical gut *district*
- An altered microbiota (dysbiosis) is strictly linked to some pathologies
- Some probiotics can be then functional on the management of these pathologies, with an innovative and unconventional approach, modulating microbiota
- Cerbios is focused on R&D of new probiotic-based formulations; clinically proven.





1. Drug product

SF68® CAPS

Cerbios is owner of the probiotic active ingredient ***E. lactis* SF68®** (formerly *E. faecium*) strain deposit number NCIMB 10415, manufactured under pharmaceutical GMP's.

Its formulation is registered as drug product in several Countries for treatment of *acute diarrhea* (adult and children), prevention of *traveler's diarrhea* and *diarrhea by antibiotics* (dysbiosis).

More than 20 clinical trials published.

A CTD and CPP from Switzerland is available.

Cerbios is continuously searching for commercial Partners interested to distribute **SF68®caps** in their Country.

Research

Cerbios supported an extensive clinical and pre-clinical research on SF68®: outcomes are the discovery of unique characteristics of this specific strain, confirmed by a significant number of publications. Its efficacy and safety profile is confirmed also by a recent review issued in 2018 but mainly by its sales history:

+100 million: More than 100 million of patients treated

+40 years: 40 years of successful commercialization

Product	Indication	Form	Category
SF68® (drug)	Treatment and prevention of diarrhea (travellers, infective), dysbiosis by antibiotics	Caps	Pharma
SF68® (Food supplement)	Treatment and prevention of diarrhea (travellers, infective), dysbiosis by antibiotics	Caps	Food Supplement
SF68® SkinActive	Maintenance of normal skin	Sachets	Food Supplement
SF68® Slipido	Maintenance of normal blood levels of cholesterol and normal metabolism of homocysteine	Sachet	Food Supplement
SF68® IBSoft	Dietary management of colonopathies with altered trophism of the intestinal mucosa	Sachets	Food Supplement
SF68® Immunoblase	Immune system	Sachets	Food Supplement



2. Finished Products list

(based on probiotic SF68®)

Given the increasing interest on microbiota and its role over the gut and the efficacy of probiotics on prevention, diagnosis and treatment of various pathologies, Cerbios is engaged to further investigate potential applications of its strain in different areas.

- ***E. lactis* SF68®** combined with other different *functional ingredients*, for unique formulations.
- *Claims approved* by EFSA
- Cerbios supports the efficacy of its Products with *clinical trials* and scientific evidences.
- Regulatory status: FS or FSMPs

PATHOLOGIES	R&D & PROOF OF CONCEPT	INDUSTRIAL VALIDATION	CLINICAL TRIAL SCIENTIFIC EVD.	REGISTRATION FILE READY FOR SUBMISSION
ACNE & SEBORRHEIC DERMATITIS	✓	✓	✓	✓
IMMUNE SYSTEM	✓	✓	✓	✓
DYSLIPIDEMIA, OBESITY, METABOLIC SYNDROME	✓	✓	✓	✓
IBS (IRRITABLE BOWEL SYNDROME)	✓	✓	Scheduled for Q1-2026	Scheduled for Q1 2026

SF68® SKINActive:

ACNE & SEBORRHEIC DERMATITIS

Rationale:

Relationship between gut and skin has been supposed on 30's. Now cumulative evidences are confirming the presence of a *gut-brain-skin axis* that connects intestinal bacteria, stress/emotions, and diet, to acne severity and other skin conditions.

Product:

*E. lactis*SF68 (10⁹ cfu/dose) in association with Niacine.

Presentation:

20 or 30 oro-dispersible sachets

EFSA claims for Niacine.

Status: ☒ **FOOD SUPPLEMENT READY FOR SUBMISSION**

(Compatibility data, formulation studies, industrialization, stabilities and clinical trial available).

Scientific evidences:

- Literature evidence, for Niacine, as sebum production regulator, keratinocytes differentiator (cellular turnover) & anti-oxidant activity.
- Clinical trial on 25 patients with significant *clinical* and instrumental results on reduction of papules, pustules and seborrhea (publication on JPD vol. 17 n.3 9-2021, pp 71-77).

SF68[®] SLIPIDO

DYSLIPIDEMIA & CARDIO METABOLIC CONDITIONS

Rationale:

Alterations of gut microbiota (*dysbiosis*) are often connected to a metabolic unbalance, like dyslipidemia (cholesterol), glucose resistance, overweight and to an *inflammatory status*, that is predictive of a potential development of obesity.

Cerbios formulated its proprietary probiotic strain with other selected functional ingredients, targeting above mentioned conditions and acting at different levels. Efficacy of the product by *preclinical* and *clinical* tests.

Product: *E.lactis* SF68 (10⁹ cfu/dose) in association with *Phytosterols* and *5-MTHF* (folate biologically active)
EFSA claims for phytosterols and 5-MTHF (folate)

Presentation: 20 or 30 oro-dispersible sachets

Status:  **FOOD SUPPLEMENT READY FOR SUBMISSION** (EU standard Technical File with stability studies).

Scientific evidences:

- Probiotics can reduce inflammatory status. regulate lipids metabolism, with various mechanism of actions, maintain intestinal barrier integrity and reduce body weight/fat.
- Phytosterols reduces blood cholesterol levels (LDL).
- Folic acid is involved on *homocysteine metabolism*, reducing its bloody concentration (high levels are linked to an increased cardiovascular risk). Here folic acid is present as the *biologically active form* of folate, 5-MTHF.
- 2 Preclinical data available and published University of Pisa (↓ inflammation, ↑ gut barrier, ↑ microbiota on mice).

Clinical trial finalized on Q4-2024 (Florence University):

↓ weight, blood lipidic profile, oxidative stress;
↑ microbiota & gut barrier.



SF68[®] IBSoft

IRRITABLE BOWEL DISEASE - Pipeline 2026

Rationale:

IBS is one of most common GI disease, (constipation or diarrhea, visceral pain, swelling), representing a unmet medical need, due to unsatisfactory treatments on the market. Has been demonstrated that a *dysbiosis* is often associated to IBS. In prevention and treatment of IBS, some specific probiotic strains (efficacy strain-specific), can be indicated for management of IBS.

Postbiotics, like butyrate (SCFA) have an additive effect on symptoms.

Product:

E.Lactis SF68 (10⁹ cfu/dose) in association with *Butyrate*.

Presentation: 30 caps

Status:  **FOOD FOR SPECIAL MEDICAL PURPOSES.**

Scientific evidences:

- SF68 demonstrated efficacy on *prevent* and *treat IBS symptoms* at pre-clinical level, *reduce inflammatory status* and increase intake of butyrate by GI cells.
- Butyrate is well known in literature for its anti-inflammatory and immunomodulant effects.

Clinical trial planned for Q1-2026.

SF68[®] Immunoblase

IMMUNITY BOOSTER

Rationale:

Intimate relationship between *gut microbiota* and *immune system* is well known since many years; in fact most of immune cells are located into intestine.

Several scientific evidences confirm use of probiotics to *boost immune response*. .

Product:

*E.lactis*SF68 (10⁹ cfu/dose) in association with Vitamin D, Selenium, Zinc and Folic acid as 5-MTHF (the active form of folic acid).

EFSA claims on supporting immune system.

Presentation: : 20 oro-dispersible sachets (1 x day).

Status: ☒ **FOOD SUPPLEMENT READY FOR SUBMISSION**
(compatibility data, formulation studies available).

Scientific evidences:

- Literature (for vitamins and probiotics)
- Preclinical data (for SF68) on enhancing immune responses and potentiating efficacy of vaccination.